BioLineRx Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q2 Results; BL-8040 Continues to be Main Driver
August 20, 2015 12:40 PM EDTRoth Capital affirms BioLineRx (NASDAQ: BLRX) with a Buy rating and $7 price target after BLRX reported quarterly results earlier Thursday.
BLRX posted Q2 EPS of ($0.12), which was $0.04 worse than the analyst estimate of ($0.08).
Analyst Joseph Pantginis offered the following commentary, We currently view BL-8040 as the main value driver for the company with multiple near-term milestones expected. The most significant... More
BioLineRx (BLRX) Misses Q2 EPS by 4c
August 20, 2015 7:05 AM EDTBioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08).
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
... More